Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alt-2074
- Development stage
- Phase 2
- Lead developer
- Synvista Therapeutics
- Modality
- Small Molecules
- Administration
- Topical, Oral
01
Overview
ALT-2074 is a small molecule organoselenium compound that acts as a glutathione peroxidase mimetic. It catalyzes the reduction of hydroperoxides to less toxic species using glutathione as the reducing agent, thereby preventing free radical formation and tissue damage. ALT-2074 also downregulates gene transcription leading to inflammatory mediators and inhibits TNF-alpha-induced expression of cell adhesion molecules such as I-CAM and V-CAM. It has been investigated for use in cardiovascular disorders, diabetes mellitus type 1 and type 2 (especially in patients with coronary artery disease), plaque psoriasis (as a topical formulation), and ulcerative colitis. The drug reached Phase II clinical trials but has not advanced further[1][2][3][5][8].
- Other names
- 173026-17-0
02
Targets
GPX4 (Glutathione peroxidase 4)
Beyond the preview
Go deeper on alt-2074.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alt-2074.